← Back to Search

COVID-19 Testing for Pregnancy (STOPCOVID19 Trial)

N/A
Waitlist Available
Led By Megan E Foeller, MD
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at time of delivery
Awards & highlights

STOPCOVID19 Trial Summary

This trial will help inform best practices for testing and care for pregnant women with COVID-19.

Who is the study for?
This trial is for pregnant women without prior SARS-CoV-2 infection (unexposed group) and those with a viable pregnancy who have tested positive or developed antibodies during their current pregnancy (exposed group). Women with no viable intrauterine pregnancy or evidence of previous COVID-19 immunity are excluded.Check my eligibility
What is being tested?
The study tests for the presence of SARS-CoV-2 through RNA, IgM, and IgG antibody testing in pregnant women. It aims to understand the necessity of asymptomatic disease testing in pregnancy and its impact on prenatal care plans.See study design
What are the potential side effects?
Since this trial involves diagnostic testing rather than medication or vaccines, direct side effects from interventions are minimal but may include discomfort or bruising from blood draws.

STOPCOVID19 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time of delivery
This trial's timeline: 3 weeks for screening, Varies for treatment, and time of delivery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of preterm delivery
Secondary outcome measures
Confirmed congenital infection
Low birth weight
Percentage of infants with abnormal umbilical cord gas
+15 more

STOPCOVID19 Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Exposed (SARS-CoV-2 positive) cohortActive Control2 Interventions
Women who experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.
Group II: Unexposed (SARS-CoV-2 negative) cohortPlacebo Group1 Intervention
Women who do not experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,931 Previous Clinical Trials
2,299,289 Total Patients Enrolled
1 Trials studying Coronavirus Infection
31 Patients Enrolled for Coronavirus Infection
Mercy ResearchOTHER
19 Previous Clinical Trials
997 Total Patients Enrolled
Megan E Foeller, MDPrincipal InvestigatorWashington University School of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19
Jeannie Kelly 2021. "Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04718220.
All > Coronavirus > Pregnancy
~31 spots leftby Aug 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top